Angiotensin receptor blocker

Phase 3Small molecule

NNational University of Ireland, Galway, Ireland

Angiotensin receptor blocker is one of 6 small molecule programs targeting Transcatheter Aortic Valve Replacement. It is currently in Phase 3.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Transcatheter Aortic Valve ReplacementNot yet recruiting

Diabetic Kidney DiseaseNot yet recruiting

Transcatheter Aortic Valve ReplacementPhase 3

Not yet recruiting

Diabetic Kidney DiseasePhase 3

Not yet recruiting

Competition

Competitive Landscape

8 competitors in Diabetic Kidney Disease

#DrugCompanyPhaseTrials

Kerendia

Bayer

Approved

2 2

Jardiance

Boehringer Ingelheim

Approved

2 3

Mazdutide

Eli Lilly

Phase 3

1 4

Angiotensin receptor blocker

NNational University of Ireland, Galway, Ireland

Phase 3

1 5

R3R01

RRiver 3 Renal Corp.

Phase 2

1 6

AP303 150μg

AAlebund Pharmaceuticals

Phase 1

—

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q2 2029

ApprovedNot yet recruiting

Diabetic Kidney Disease

NCT07775846

Q2 2030

ApprovedNot yet recruiting

Transcatheter Aortic Valve Replacement

NCT07735130

Clinical

Trials by Indication[1]

COVID-191 trial

Coronavirus (COVID-19) ACEi/ARB Investigation

Suspended·NNational University of Ireland, Galway, Ireland·Phase 4·NCT04330300·2,414 enrolled

Diabetic Kidney Disease1 trial

QUAdruple Therapy With RASi, Empagliflozin, Finerenone, and Mazdutide in Type 2 Diabetes and Early Treatment of Nephropathy(QUARTET-DKD)

Not yet recruiting·HHuijie Zhang·Approved·NCT07775846·820 enrolled

Transcatheter Aortic Valve Replacement1 trial

Angiotensin Receptor Blockade In Patients After Transcatheter Aortic Valve Replacement for Severe Aortic Stenosis With Left Ventricular Hypertrophy (ARBITAR) Trial

Not yet recruiting·SSeoul National University Hospital·Approved·NCT07735130·632 enrolled

Sources

References

[1]
ClinicalTrials.gov — 3 trial records for Angiotensin receptor blocker. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Angiotensin receptor blocker compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Angiotensin receptor blocker. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — National University of Ireland, Galway, Ireland company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 3[1]
Company: NNational University of Ireland, Galway, Ireland

Angiotensin receptor blocker

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q2 2029

Q2 2030

Trials by Indication[1]

COVID-191 trial

Diabetic Kidney Disease1 trial

Transcatheter Aortic Valve Replacement1 trial

References

Drug Info

Quick Facts

Related News